10025-87-3

The reaction of ClONO2 with PCl3 yields POCl3 and NO2+NO3-. With AsCl3 chlorine nitrate forms a compound of the analytical composition AsCl2(NO3)3 , in contrast to SbCl3, which does not react with ClONO2. The reaction of ClONO2 with AsCl4+AsF6- was reported to yield As(ONO2)4+AsF6-. We found no reaction below 273 K. Reaction at 293 K yields NO2+AsF6- as solid product. SbCl5 does react, but the reaction yields no reproduceable products.

PCl3-O3 and PBr3-O3 complexes in solid argon photolyze to give phosphoryl halides with red visible radiation that has no effect on isolated ozone.These observations and similar results for PH3-O3 and P4-O3 complexes show that the complex markedly increases the cross section for red photodissociation of ozone and suggest that this increase is due to the complex effectively lowering the barrier to dissociation by providing a strongly exothermic dissociation-recombination process.

The reaction of FePO//4 with molten CsCl produces Cs//3Fe//4(PO//4)//5, Cs//7Fe//7(PO//4)//8O//2, or Fe//2O//3, depending on the length of the reaction. The crystal structure of Cs//3Fe//4(PO//4)//5 consists of an interlocking network of corner-sharing phosphate tetrahedra and iron trigonal bipyramids with cesium atoms situated in tunnels. The Cs//7Fe//7(PO//4)//8O//2 structure can be described as a three-dimensional array containing linked phosphate tetrahedra and iron octahedra, trigonal bipyramids, and square pyramids. In addition to the phosphate oxygen atoms, three of the iron polyhedra share a common oxide ion. The cesium atoms are located in tunnels.

Rate constants and product ion branching fractions for the gas-phase reactions of O2 and O3 with the anions (a) PO 2Cl-, (b) POCl3-, (c) POCl 2-, and (d) PO2Cl2- were measured in a selected-ion flow tube (SIFT). The kinetics were measured at temperatures of 163-400 K and a He pressure of 0.4 Torr. Only PO 2Cl- reacts with O2 to a measurable extent, having k(163-400 K) = 1.1 × 10-8(T/K)-1.0 cm 3 molecule-1 s-1, while O3 reacts with all of the anions except PO2Cl2-. The fitted rate constant expressions for the O3 reaction with anions a-c are as follows: ka(163-400 K) = 3.5 × 10-6(T/K) -1.6, kb(163-400 K) = 4.0 × 10 -7(T/K)-1.2, and kc(163-400 K) = 3.7 × 10-7(T/K)-1.4 cm3 molecule-1 s -1. Calculations were performed at the G3 level of theory to obtain optimized geometries, energies, and electron affinities (EAs) of the reactant and product species, as well as to determine the reaction thermochemistry to help understand the experimental results. The POxCly - anions that have lower electron binding energies (eBE) and higher spin multiplicities are more reactive. The doublets are more labile than the singlets. How the extra electron density is distributed in the anion does not predict the observed reactivity of the ion. The reactions of PO 2Cl- with O2 and O3 yield predominantly PO3- and PO4-. The reaction of POCl2- with O3 yields mostly Cl- and PO2Cl2-, while the POCl 3- reaction with O3 yields mostly O 3- and PO2Cl2-.

Primary intermediates of P(III) chlorides reaction with aldehydes have been converted into the corresponding phosphates by treating with oxidants: dimethylsulfoxide and tert-butyl hypochlorite. In reactions of the intermediates with chlorinating agents (P

-

Oxygen atom transfer (OAT) reagents are common in biological and industrial oxidation reactions. While many heterogeneous catalysts have been utilized in OAT reactions, heterogeneous OAT reagents have not been explored. Here, cross-linked poly(4-vinylpyridine-N-oxide), called x-PVP-N-oxide, was tested as a heterogeneous OAT reagent and its oxidation chemistry compared to its molecular counterpart, pyridine-N-oxide. The insoluble oxidant x-PVP-N-oxide demonstrated comparable reactivity to pyridine-N-oxide in direct oxidation reactions of phosphines and phosphites in acetonitrile, but x-PVP-N-oxide did not react in other solvents. The polymer backbone of x-PVP-N-oxide, however, allowed for easy filtering and recycling in sequential oxidation reactions. In addition, x-PVP-N-oxide was tested as the stoichiometric oxidant in a copper-catalyzed OAT reaction to α-diazo-benzeneacetic acid methyl ester. The heterogeneous oxidant was much less reactive than pyridine-N-oxide, indicating that interaction with the metal catalyst was challenging. These results demonstrated a proof-of-concept that recyclable, polymer-supported OAT reagents could be a viable OAT reagents in direct oxidation reactions without metal catalysts.

-

An improved and efficient synthesis of pinene based two bipyridyldiols and bipyridine is reported. For the first time, the sealed tube-pressure reaction of pinene based pyridone with phosphoryl chloride produced an excellent yield (95%) of pinene based 2-chloropyridine, which renders synthesizing pinene based bipyridyldiols a highly inexpensive and high yielding process. Moreover, highly effective reaction condition was developed for homocoupling of chloropyridine with Ni(0) that afforded pinene based bipyridine in a high yield (84%). These newly demonstrated sealed tube-pressure chlorination and homocoupling reaction of chloropyridine afford extremely effect route for the synthesis of pinene based bipyridine.

The invention discloses a method for co-producing high-purity phosphorus oxychloride by alkyl phosphonic acid monoalkyl ester, and the method comprises the following steps: (1) reacting phosphorus pentachloride and alkyl phosphonic acid dialkyl ester in a

An organic electroluminescent element comprising an anode, a cathode and a plurality of organic compound layers sandwiched between the anode and cathode, the organic compound layers including: a hole-transporting layer made of an organic compound insoluble in alcohols; and an electron-transporting layer formed on the hole-transporting layer by a wet method, the electron-transporting layer being made of a phosphorus-containing organic compound soluble in the alcohols.

The reactions between CrO2Cl2 and a series of substituted phosphines have been investigated using matrix isolation infrared spectroscopy. For all of the phosphines except PF3, twin jet co-deposition of the two reagents into argon matrices at 14 K initially led to the formation of weak bands due to the corresponding phosphine oxide. For all of the phosphines, subsequent irradiation with light of λ > 300 nm led to the growth of a number of intense new bands that have been assigned to the phosphine oxide complexed to CrCl2O, following an oxygen atom transfer reaction. Gas-phase, merged jet reactions prior to matrix deposition led to a significant yield of the uncomplexed phosphine oxide. Theoretical calculations at the B3LYP/6-311++g(d,2p) level were carried out in support of the experimental work, to support product band assignments and clarify the nature of the molecular complexes.

This invention is directed to functionalized higher diamondoids having at least one functional group. Preferably these derivatives have the following Formula I: wherein D is a higher diamondoid nucleus and wherein R1, R2, R3/su

Disclosed is a flame-retardant composition including an oligomer-type flame-retardant compound represented by formula 1, which gives good flame retardation, heat-resistance, hydrolysis-resistance and fluidity characteristics to resin. (wherein, n is an in

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH═CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

The subject invention involves compounds having the structure: wherein the Cα—Nβ, C5-C6, and C6-C7bonds are each single or double bonds, except that both C5-C6, and C

The invention relates to a process for making DCSA by cyclization of DCM-ATSA with an acid and phosphorus pentachloride to produce DHSA and two isomeric compounds known as HCSA. The resulting compounds from the cyclization are halo-dehydroxylated to produ

The invention relates to a novel process for preparing 4,6-dichloro-5-fluoropyrimidine.

There are described 7H-pyrrolo[2,3-d]pyrimidine derivatives of the formula I in which the substituents are as defined in claim 1. These compounds inhibit the tyrosine kinase activity of the receptor for the epidermal growth factor (EGF) and c-erbB2 kinase and can be used as anti-tumor agents.

The present invention provides beta -carboline derivatives useful as components of cosmetic, medicinal, and pharmaceutical compositions. The medicinal and pharmaceutical compositions can be used to induce hypnotic activity in a subject. Methods of producing the beta -carboline derivatives are provided as well.

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

The present invention relates to novel pyrimidine derivatives of the formulae (I-1) and (I-2) and pharmaceutically acceptable salts thereof which possess an excellent anti-secretory activity, pharmaceutical compositions containing same as an active ingredient, their novel intermediates, and processes for the preparation thereof: STR1 wherein: R4 and R5, which may be the same or different, are independently hydrogen or a C1 -C3 alkyl group, or jointly form a cyclopentyl or cyclohexyl ring; A is a group of formula(II): STR2 wherein R1 and R2 are, independently of each other, hydrogen or a C1 -C3 alkyl group, and R3 is hydrogen, a C1 -C3 alkyl group or a halogen; and B is 1-(substituted)-1,2,3,4-tetrahydroisoquinolin-2-yl of formula (III-1) or 7-(substituted)-4,5,6,7-tetrahydrothieno?2,3-c!pyridin-6-yl of formula (III-2) STR3 wherein R6 is hydrogen or a C1 -C3 alkyl group.

A novel, simple, high-yield process for the production of 2,3,5,6-tetrachloropyridine comprises reacting an ester of 2,2,4-trichloro-4-cyanobutyric acid with excess phosphorus oxychloride in the presence of a catalytic amount of hydrogen chloride and optionally in the presence of an aprotic inert solvent, at a temperature of 100°-160° C., preferably at 120°-140° C. for about 5-10 hours, under elevated pressure, if necessary.

An improved process for the preparation of 2,3,5,6-tetrachloropyridine of the formula STR1 consists in that 3,3,5-trichloroglutarimide of the formule STR2 is reacted either a. with phosphorus trichloride or phosphorus oxytrichloride or mixtures thereof in

Raman (3500-50 cm-1) and infrared (4000-400 cm-1) spectra of the title compound, ClSO2N=PCl3, were recorded for the solid and liquid phase. Additionally, the Raman spectrum of the compound dissolved in CCl4, was obtained and qualitative depolarization values were determined. The spectra of the liqud and solid phase were interpreted in terms of the existence of only one conformation possessing C1 symmetry, as predicted by quantum chemical calculations. A complete vibrational assignment is proposed based on the relative intensities, on group frequencies along with support from the normal coordinate analysis. The experimental fundamental vibrational modes are compared to those obtained from theoretical approaches employing the ab initio MP2/6-31G* method and a density functional approximation (B3PW91/6-31G*). Keywords: Trichlorophosphoranylidenesulfamoyl chloride / Vibrational spectroscopy / Conformational properties / Quantum chemical calculations VCH Verlagsgesellschaft mbH.

The present invention relates to a silicon-containing material which exhibits sufficient hydrophilicity and sufficient electropositivity to bind DNA from a suspension containing DNA and permit elution of the DNA from the material. Generally, the hydrophilic and electropositive characteristics are expressed at the surface of the silicon-containing material. Preferred silicon-containing materials of the present invention include boron silicate, aluminum silicate, phosphosilicate, silica carbonyl, silica sulfonyl and silica phosphonyl. The silicon-containing materials of the present invention are particularly useful in processes for purification of DNA from other cellular components. In these processes, a suspension of cellular components is placed in contact with the silicon-containing material, the silicon-containing material is washed to remove all cellular components other than DNA which are bound to the material, and the bound DNA is eluted from the material. Several of the silicon-containing materials are capable of binding and eluting DNA using only water.

Coarse crystalline (NH2)2(O)P-N=P(NH2)3 is obtained from a NH3 saturated CH2Cl2 suspension of (NH2)2(O)P-N=P(NH2)3·NH 4Cl at room temperature. (NH2)2(O)P-N=P(NH2)3·NH 4Cl is synthesized by slow addition of Cl2(O)P-N=PCl3 to a solution of NH3 in CH2Cl2 at -78 °C. Excess NH4Cl is removed by treatment with HNEt2 followed by extraction with CH2Cl2. The crystal structure of (NH2)2(O)P-N=P(NH2)3 has been determined by single crystal X-ray methods (P21/c; a = 1462.8(3) b = 944.8(2), c = 1026.9(2) pm, β= 110.69(3)°; Z = 8). In the unit cell there are two crystallographically unique molecules. They form a three dimensional network by intermolecular hydrogen bonding interactions (N-H...N ≥ 313 pm, N-H-...O ≥ 293 pm). The investigation of the thermal properties shows decomposition with evolution of NH3 above 80°C.

According to the invention, a new process has been found for the preparation of 2,2-difluoro-benzo[1,3]-dioxole-carbaldehydes of the formula (I) STR1 in which benzo[1,3]dioxole-carbaldehydes are chlorinated, the 2,2-dichloro-dichloromethylbenzo[1,3]dioxoles formed, which are likewise new, are partly fluorinated to give the 2,2-difluoro-dichloromethyl-benzo[1,3]dioxoles, which are likewise new, and these are then reacted with urotropin to give the desired compounds.

The present invention encompasses compounds of formula I: STR1 and the pharmaceutically acceptable non-toxic salts thereof; wherein R 1 is hydrogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, or phenylalkyl;R 2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, or phenylalkyl; orNR 1 R 2 forms a nitrogen heterocycle; andR 3 is hydrogen, an amino acid or a peptide residue.These compounds may be employed as substrates in assays for determining proteolytic enzyme activity or as enzyme inhibitors. The invention also encompasses methods for determining proteolytic enzyme activity using the compounds of formula I.

This invention pertains to phosphosulfonates, having the general formula STR1 wherein Y is phenyl, naphthyl, benzyl, a (C5 -C8)cycloalkyl, a 5-membered heteroaromatic ring, a 6-membered heteraromatic ring, a fused 5,6-membered heteroaromatic ring, or a fused 6,6-membered heteroaromatic ring; and X is oxygen or sulfur; and R1 and R2 are each independently selected from substituted or unsubstituted alkyl, alkoxy, alkylthio, alkenyloxy, alkynyloxy, haloalkoxy, cyanoalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkoxy, alkylideneiminooxy, chloro, amino, phenyl or phenoxy; or R1 and R2 are both alkoxy, taken together with the phosphorus atom to form a 6-membered oxygen-containing ring; compositions containing these compounds and their use as herbicides.

Potassium magnesium L-ascorbate 2-phosphate is prepared from an aqueous solution of potassium L-ascorbate 2-phosphate which is highly contaminated with KCl, as is produced in the phosphorylation of 5,6-isopropylidene-L-ascorbic acid, by adding to the solu

-

Compounds of the formula STR1 wherein R5 represents C1 to C6 -alkyl or the group--(CH2)n --Z--(CH2)m --Ar wherein Z represents O, S or --CH2 --and Ar is phenyl, optionally substituted by one or two groups selected from the group consisting of hydrogen, C1 to C6 -alkyl, C1 to C6 -alkoxy, Cl,F,Br,I,NO2, CF3, CN, R6 -S(O)x, R7 --CO--,(R8 R9)NCO-and phenyl, wherein x is 0, 1 or 2, and each R6, R7, R8 and R9 is independently C1 to C6 alkyl or two adjacent groups on Ar may form together an additional fused benzenoid ring; n and m independently represent integers of from 1 to 8; and ring Q represents one of the rings Q1, Q2, Q3 or Q4 below: STR2 X is N or C--R1 ; Y is N or C--R4 ; W represents O or S; each of R1, R2, R3 and R4 is independently selected from hydrogen, C1 to C6 -alkyl, C1 to C6 -alkoxy, Cl,F,Br,I,NO2,CF3,CN, R10 -S(O)y --, R11 --CO--, (R12 R13)N--CO--or phenyl, wherein y is 0, 1 or 2 and each of SR10, R11, R12 and R13 is independently C1 to C6 -alkyl, or, in the ring Q1, two adjacent groups, i.e. R1 R2, R2 R3 or R3 R4, may form together an additional fused benzenoid ring; and pharmaceutically acceptable acid addition salts of such compounds are described. These compounds provide favorable properties for the treatment of asthma and all types of chronic, obstructionary bronchopulmonary diseases.

5,7-Dihydroxy-N-(aryl)-1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides are prepared by the cyclization of N-(3-(((aryl)amino)sulfonyl)-1H-1,2,4-triazol-5-yl)amines with malonyl halides under acidic conditions. With the addition of a phosphorus oxyhalide, m

The present invention relates to an industrially advantageous process for producing 2-amino-4,6-dichloropyrimidine, which comprises reacting 2-amino-4,6-dihydroxypyrimidine or its salt with phosphorus oxychloride at a temperature of from 50° to 100° C. in the presence of a solvent and an acid removing agent. Further, the yield of 2-amino-4,6-dichloropyrimidine can be improved by hydrolyzing 4,6-dichloro-2-pyrimidinylphosphoramidic dichloride produced as a by-product of the chlorination reaction to form 2-amino-4,6-dichloropyrimidine. The 2-amino-4,6-dichloropyrimidine produced by the process of the present invention is useful as an intermediate for medicines and agricultural chemicals.

Novel 11β-alkynylphenyl-19-nor-steroids of the formula STR1 wherein R1 is alkynyl of 2 to 8 carbon atoms optionally substituted with at least one member of the group consisting of --OH halogen, trialkylsilyl of 1 to 6 alkyl carbon atoms, alkoxy

Compounds of formula (I): STR1 and stereoisomers thereof, wherein W is R1 O2 C--C=CH--ZR2, wherein R1 and R2, which are the same or different, are alkyl or fluoroalkyl groups, and Z is either an oxygen or sulphur atom; A is an oxygen or sulphur atom, --NR3 --, or --CR4 R5 --; X, Y and Z1, which are the same or different, are hydrogen or halogen atoms, or hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxy, optionally substituted arylalkoxy, optionally substituted aryloxy, optionally substituted heteraryloxy, optionally substituted acyloxy, optionally substituted amino, optionally substituted acylamino, optionally substituted arylazo, nitro, cyano, --CO2 R6, --CONR7 R8, --COR9 --CR=NR10, --CR=NOR10 or --N=CR11 R12 groups; or the groups X and Y, when they are in adjacent positions on the ring, optionally join to form a fused ring, either aromatic or aliphatic, optionally containing one or more heteroatoms; and R, R3, R4, R5, R6, R7, R8 R9, R10, R11 and R12, which are the same or different, are hydrogen atoms (provided that R4 and R5 are not hydrogen) or optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aralkyl, optionally substituted heterarylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted heteroaryl groups; and metal complexes thereof. The compounds are useful in agriculture, especially as fungicides but also as insecticides and plant growth regulators.

Compounds of the formula (I): STR1 and stereoisomers and salts thereof, wherein R1 and R2, are optionally substituted alkyl; V is either oxygen or sulphur; Y is hydrogen, optionally substituted alkyl, cyano, nitro or halogen; X is ST

Compounds represented by the general formula (I): STR1 in which R1 represents STR2 A and B each represent H or a lower alkane optionally substituted with amino and/or hydroxyl functions, except that A and B are not both H; R3 represe

The polychlorophosphazenes of the general formula Cl3P=N-(-PCl2=N-)n-1-P(O)Cl2 are synthetized by the polycondensation of P-trichloro N-dichlorophosphoryl monophosphazene with the controlled release of POCl3 according to the equation n Cl3PHP(O

Herbicidally active novel substituted 1-benzylsulphonyl-3-heteroaryl(thio)-ureas of the formula STR1 in which Q represents oxygen or sulphur, R1 represents hydrogen, or represents optionally substituted radicals from the series comprising alkyl

Novel insecticidally and acaricidally active compounds of the formula STR1 in which R1 is halogen or alkyl, R2 is hydrogen, halogen or alkyl, R3 is hydrogen or methyl, and X is oxygen or sulphur. Several of the intermediat

An improved process for preparing a phosphorus complex of the formula: wherein R is selected from the group consisting of: aryl; substituted aryl, wherein the substituent can comprise at least one member selected from the group consisting of nitro, chloro

The two 4,5-diethyl-2,5-dihydro-2,2-dimethyl-3-organo-1,2,5-oxasilaboroles are prepared from and water via the addition compounds in yields of about 90percent. 2a,b are also obtained directly from 1a,b with acetylacetone or with dry acetic acid. 1b can be prepared from sodium triethylhydroborate (A) via sodium triethyl(3-methyl-3-buten-1-ynyl)borate (B), (Z)-4-(diethylboryl)-2-methyl-3-(trimethylsilyl)-1,3-hexadiene (C), sodium aminodiethylborate (D), 4,5,5-triethyl-2,5-dihydro-3-isopropenyl-2,2-dimethyl-1-sodio-1,2,5-azoniasilaboratole (E), and 4,5-diethyl-2,5-dihydro-3-isopropenyl-2,2-dimethyl-1-sodio-1,2,5-azasilaborole (F).The behaviour of 2a,b towards trimethylphsophane (TMP), γ-picoline (formation of γ-Pic-2a), γ-picoline N-oxide (PNO-2a), trimethylamine N-oxide (2'a, 4, 4'a), methylenetriphenylphosphorane (MTPP-2a), aluminium trichloride (2a-AlCl3), triethylaluminium , trichloroborane (3a), dichloroethylborane (3b), phosphorus pentachloride (3a, 3b), methanol (6a), acetylacetone (5a), propanol (7a, 7c) and towards glacial acetic acid (7a, 9) is described. 5-Chloro-4-ethyl-2,5-dihydro-1,2,2,3-tetramethyl-1,2,5-azasilaborole (1c) is readily obainable from 1a and dichloroethylborane. η4-Complexations of 2b give 10b from (CH3CN)3Cr(CO)3, 11b and 11'b from Fe2(CO)9, 12b from Ru3(CO)12, 13b from C5H5Co(C2H4)2, and 14b from C5H5Rh(C2H4)2 (MS and NMR data).The O-exchange in several reactions was monitored by 17O NMR using 17O-enriched compounds (e.g. 2a*, triethylboroxin*, tetraethyldiboroxane*, water*, methanol*).

New compounds of the formula STR1 a process for their preparation and their use as intermediates for insecticides.

A process for the preparation of 2,6-dichlorobenzoxazole, which comprises reacting 6-chlorobenzoxazolone in the presence of chlorine, phosphorus trichloride and phosphoryl chloride, or in mixtures of phosphorus pentachloride and phosphoryl chloride, at te

A novel pyridine derivative which, when added to liquid crystal substances, can improve various specific features required for the resulting liquid crystal compositions, and a liquid crystal composition containing the same are provided, which pyridine der

A furyloxazolylacetic acid derivative of the formula: STR1 wherein R1 is alkyl of one to 6 carbon atoms, cycloalkyl of 5 to 6 carbon atoms, phenyl or a substituted phenyl (said substituted phenyl being phenyl group substituted with one or two r

A compound (I) of the formula: STR1 (wherein X and Y each is halogen) and herbicidal compositions containing the compound (I) are provided.

Migraine is treated with a tropyl benzoate derivative of the following general formula: STR1 wherein: R1 represents C1 -C4 alkyl, C1 -C4 alkoxy or halogen; R2 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen; and R3 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen, provided that R3 is hydrogen when R2 is hydrogen, or a pharmaceutically acceptable salt thereof. Additionally, some novel tropyl benzoate derivatives are disclosed.

Migraine is treated with a tropyl benzoate derivative of the following general formula: STR1 wherein: R1 represents C1 -C4 alkyl, C1 -C4 alkoxy or halogen; R2 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen; and R3 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen, provided that R3 is hydrogen when R2 is hydrogen, or a pharmaceutically acceptable salt thereof. Additionally, some novel tropyl benzoate derivatives are disclosed.